Atmos Energy Corporation vs GSK plc — how do they compare? Atmos Energy Corporation trades at $169.82 (market cap $28.59B), while GSK plc trades at $50.35 (market cap $102.60B). The key difference: GSK plc is far larger — about 3.6× Atmos Energy Corporation's market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| ATO | GSK | |
|---|---|---|
Market Cap | $28.59B | $102.60B |
Sector | Utilities | Health |
52-Week High | $192.25 | $61.18 |
52-Week Low | $162.44 | $38.22 |
Enterprise Value | $38.40B | $123.04B |
Dividend Yield | 2.36% | 3.57% |
Signals from Pluang's Aura AI — not financial advice
Atmos Energy (ATO) trades at $167.92, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company reported Q3 2026 EPS of $1.43, beating estimates of $1.35, with revenue growth of 4.8% year-over-year. Strong profitability metrics include a 28.5% net income margin and 62.2% gross margin, while valuation ratios show a P/E of 20.2 and P/S of 5.7. Recent corporate developments include board appointments and dividend declarations of $1.00 per share.
ATO presents a mixed outlook with solid fundamentals and analyst support but faces technical headwinds. The consensus price target of $190.57 suggests 13.5% upside potential, supported by 45% buy ratings. Risks include high capital expenditures impacting cash flow and debt levels near $7.9 billion. Earnings growth and rate approvals provide catalysts, though the stock's bearish technical trend warrants caution near-term.
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Trailing returns across standard periods
Latest headlines on both assets
Atmos Energy is the largest publicly traded, fully regulated, pure-play natural gas utility in the United States, serving more than 3 million customers in Texas, Colorado, Kansas, Kentucky, Louisiana, Mississippi, Tennessee, and Virginia. About two thirds of its earnings come from Texas, where it distributes natural gas in northern Texas and owns an intrastate gas pipeline spanning several key shale gas formations and interconnected with five storage facilities.
Read more on ATO →In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →